The "Global Dendritic Cell Cancer Vaccine Immunotherapy Market, Dosage, Price & Clinical Trials Insight 2026" report has been added to ResearchAndMarkets.com's offering.
In the past few years, significant breakthroughs in the medical research have led to the opening of novel doors to harness the immune system of the body against the cancer cells. For the very first time in the history of cancer therapeutics, researchers have discovered a cure that incorporates dendritic cells. The introduction of dendritic cell vaccine immunotherapy into the cancer therapeutics has caused several scientific and medical hurdles to overcome as the opportunities linked with dendritic cells treatment for the cancer patients are huge.
Dendritic cell vaccine immunotherapy among all the immunotherapy treatments is considered as the most potent antigen presenting cells for the proliferation of the T-cells. The uniqueness embedded in the treatment have prompted their applications to be involved in the majority of the treatments as well as wider-acceptance across the globe. The potential of immune system in fighting cancer cells got recognized three-four decades before. Since then, technological and innovative advancement in scientific knowledge has led to the development of novel ally for the cancer patients, which has now become the only hope for declining the cancer mortality rate.
The opening of novel research frontiers with the understanding of biological mechanisms underlying the human cancer and immune system are estimated to be creating promising trends and opportunities for the researchers, patients, physicians and the stakeholders. In addition, some of the factors that are leading to the exponential growth of the market in terms of revenue and size are increasing cancer cases, awareness about the advantages of the dendritic cell vaccine immunotherapy, technology advancement and many more. The dendritic cell vaccine immunotherapy market is catalyzed by a completely and exciting novel range of disruptive technologies required for the re-definition of cancer therapeutics market. In the next few years, researchers are estimated to bring a shift in the treatment paradigm where temporary respite of the cancer treatment will not be boosted in the cancer therapeutic challenge. In the new world, dendritic cell vaccine immunotherapy is estimated to be conquering all the challenges that were challenging to conquer before the arrival of the therapy.
Companies Mentioned
- 3M Company
- Activartis
- Argos Therapeutics
- Batavia Bioservices
- Bellicum Pharmaceuticals
- Creagene
- DCPrime
- DanDrit Biotech
- Dendreon Corporation
- Elios Therapeutics
- Glaxo Smith Kline
- Immunicum
- ImmunoCellular Therapeutics
- Kiromic
- Medigene
- Merck
- Northwest Biotherapeutics
- SOTIO
- Tella Incorporation
- Theravectys
- Vaxil BioTherapeutics
Report Highlights:
- Global Dendritic Cell Cancer Vaccine Clinical Trials: More than 50 Vaccines In Pipeline
- Commercially Available Dendritic Cell Cancer Vaccine: 3 Vaccines
- Dendritic Cell Cancer Vaccine Expected Launches Over Next Decade: More Than 3 Vaccines
- Majority Vaccines In Preclinical Phase: More Than 10 Vaccines
- Global Dendritic Cell Cancer Vaccine Immunotherapy Market Regional Outlook
- Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication & Phase
- Dosage, Efficacy & Price Insight of Provenge, Apceden & CreaVax
Key Topics Covered:
1. Introduction to Dendritic Cell Cancer Vaccine
2. Relevance of Dendritic Cells in Immune System & Cancer Therapy
3. Dendritic Cell Cancer Vaccines: Mechanism of Action
3.1 Manufacturing of Dendritic Cell Vaccines
3.2 Mechanism of Dendritic Cell Vaccine against Cancer Cells
4. Dendritic Cell Cancer Vaccine In Combination Therapy
4.1 Radiotherapy
4.2 Monoclonal Antibodies
5. Research & Technological Collaborations for Advancing the Dendritic Cell Immunotherapy Market
6. Global Dendritic Cell Cancer Vaccine Immunotherapy Current Market Overview
7. Dendritic Cell Cancer Vaccine Immunotherapy Market Regional Outlook
7.1 North America
7.2 India
7.3 South Korea
7.4 Japan
8. Global Dendritic Cell Cancer Vaccine Immunotherapy Clinical Trials Landscape
8.1 By Phase
8.2 By Patient Segment
8.3 By Company
8.4 By Country
8.5 By Cancer
9. Dendritic Cell Cancer Vaccine Immunotherapy - Dosage, Efficacy & Price Insight
10. Comparative Assessment of Provenge v/s other Therapeutics for Prostate Cancer
11. Global Dendritic Cell Vaccines Immunotherapy Clinical Pipeline By Company, Indication & Phase
12. Marketed Dendritic Cell Vaccines Immunotherapy Clinical Insight
12.1 CreaVax
12.2 Sipuleucel-T (Provenge)
12.3 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical
13. Promising Future of Dendritic Cell Vaccines in Various Cancer
13.1 Dendritic Cell Vaccine in Stage-III Melanoma
13.2 Dendritic Cell Vaccine in Acute Myeloid Leukemia
13.3 Dendritic Cell Vaccine in Brain Tumor
14. Global Dendritic Cell Cancer Vaccine Market Dynamics
14.1 Favorable Market Parameters
14.2 Market Growth Challenges
15. Global Dendritic Cell Cancer Vaccine Market Future Outlook
16. Competitive Landscape
For more information about this report visit https://www.researchandmarkets.com/r/i7f8oj
View source version on businesswire.com: https://www.businesswire.com/news/home/20201023005361/en/
Contacts:
Laura Wood, Senior Press Manager
press@researchandmarkets.com
